Coleen Hall

1.2k total citations
18 papers, 927 citations indexed

About

Coleen Hall is a scholar working on Epidemiology, Neurology and Hepatology. According to data from OpenAlex, Coleen Hall has authored 18 papers receiving a total of 927 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Epidemiology, 8 papers in Neurology and 7 papers in Hepatology. Recurrent topics in Coleen Hall's work include Parkinson's Disease Mechanisms and Treatments (8 papers), Hepatitis C virus research (7 papers) and Hepatitis B Virus Studies (6 papers). Coleen Hall is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (8 papers), Hepatitis C virus research (7 papers) and Hepatitis B Virus Studies (6 papers). Coleen Hall collaborates with scholars based in United States, Egypt and Australia. Coleen Hall's co-authors include Krai Chatamra, Janet Benesh, Susan Eaton, John T. Slevin, Hubert H. Fernandez, Edward Tam, Rebecca Redman, Victor S.C. Fung, Regis A. Vilchez and Niloufar Mobashery and has published in prestigious journals such as The Lancet, Gastroenterology and Neurology.

In The Last Decade

Coleen Hall

17 papers receiving 909 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Coleen Hall United States 11 483 434 357 87 79 18 927
Axel Hinzpeter Germany 8 200 0.4× 32 0.1× 217 0.6× 27 0.3× 25 0.3× 8 387
N. Ueda Japan 13 89 0.2× 29 0.1× 32 0.1× 228 2.6× 87 1.1× 23 722
A. Penne Italy 7 58 0.1× 36 0.1× 131 0.4× 15 0.2× 100 1.3× 13 296
Luisa Sestito Italy 9 128 0.3× 51 0.1× 22 0.1× 11 0.1× 36 0.5× 16 392
Tatiana Vander Israel 7 56 0.1× 40 0.1× 10 0.0× 24 0.3× 24 0.3× 13 293
Kathy Chi‐Burris United States 5 89 0.2× 332 0.8× 5 0.0× 53 0.6× 145 1.8× 9 677
Samantha Molsberry United States 14 51 0.1× 167 0.4× 3 0.0× 87 1.0× 31 0.4× 26 479
Michael Peeters Belgium 8 22 0.0× 102 0.2× 57 0.2× 62 0.7× 23 0.3× 14 267
Isabel Pastor Spain 12 216 0.4× 24 0.1× 56 0.2× 6 0.1× 98 1.2× 23 478

Countries citing papers authored by Coleen Hall

Since Specialization
Citations

This map shows the geographic impact of Coleen Hall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Coleen Hall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Coleen Hall more than expected).

Fields of papers citing papers by Coleen Hall

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Coleen Hall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Coleen Hall. The network helps show where Coleen Hall may publish in the future.

Co-authorship network of co-authors of Coleen Hall

This figure shows the co-authorship network connecting the top 25 collaborators of Coleen Hall. A scholar is included among the top collaborators of Coleen Hall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Coleen Hall. Coleen Hall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Fernandez, Hubert H., James T. Boyd, Victor S.C. Fung, et al.. (2018). Long‐term safety and efficacy of levodopa‐carbidopa intestinal gel in advanced Parkinson's disease. Movement Disorders. 33(6). 928–936. 69 indexed citations
2.
3.
Schnell, Gretja, Rakesh Tripathi, Jill Beyer, et al.. (2018). Characterization of demographics and NS5A genetic diversity for hepatitis C virus genotype 4‐infected patients with or without cirrhosis treated with ombitasvir/paritaprevir/ritonavir. Journal of Viral Hepatitis. 25(9). 1078–1088. 3 indexed citations
4.
Standaert, David G., Ramon L. Rodriguez, John T. Slevin, et al.. (2017). Effect of Levodopa‐carbidopa Intestinal Gel on Non‐motor Symptoms in Patients with Advanced Parkinson's Disease. Movement Disorders Clinical Practice. 4(6). 829–837. 49 indexed citations
5.
6.
Antonini, Angelo, Victor S.C. Fung, James T. Boyd, et al.. (2016). Effect of levodopa‐carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients. Movement Disorders. 31(4). 530–537. 69 indexed citations
7.
Slevin, John T., Hubert H. Fernandez, Cindy Zadikoff, et al.. (2015). Long-Term Safety and Maintenance of Efficacy of Levodopa-Carbidopa Intestinal Gel: An Open-Label Extension of the Double-Blind Pivotal Study in Advanced Parkinson's Disease Patients. Journal of Parkinson s Disease. 5(1). 165–174. 85 indexed citations
8.
9.
Lawitz, Eric, Mihály Makara, Ulus Salih Akarca, et al.. (2015). Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis. Gastroenterology. 149(4). 971–980.e1. 68 indexed citations
10.
11.
Schnell, Gretja, Rakesh Tripathi, Jill Beyer, et al.. (2015). Hepatitis C Virus Genotype 4 Resistance and Subtype Demographic Characterization of Patients Treated with Ombitasvir plus Paritaprevir/Ritonavir. Antimicrobial Agents and Chemotherapy. 59(11). 6807–6815. 36 indexed citations
12.
13.
Antonini, Angelo, Victor S.C. Fung, James T. Boyd, et al.. (2014). Changes In Troublesome Dyskinesia And Its Relationship With Dose In Advanced Parkinson’s Disease Patients Treated With Levodopa-Carbidopa Intestinal Gel Infusion (P7.071). Neurology. 82(10_supplement). 1 indexed citations
14.
Fernandez, Hubert H., David G. Standaert, Robert A. Hauser, et al.. (2014). Levodopa‐carbidopa intestinal gel in advanced Parkinson's disease: Final 12‐month, open‐label results. Movement Disorders. 30(4). 500–509. 187 indexed citations
15.
Haig, George M., Yili Pritchett, Andreas Meier, et al.. (2014). A Randomized Study of H3 Antagonist ABT-288 in Mild-To-Moderate Alzheimer's Dementia1. Journal of Alzheimer s Disease. 42(3). 959–971. 61 indexed citations
16.
17.
Haig, George M., Andreas Meier, Yili Pritchett, et al.. (2012). P3‐417: Evaluation of the efficacy and safety of the H3 antagonist ABT‐288 in mild‐to‐moderate Alzheimer's disease. Alzheimer s & Dementia. 8(4S_Part_16). 7 indexed citations
18.
Wilens, Timothy E., Laura M. Gault, Ann Childress, et al.. (2010). Safety and Efficacy of ABT-089 in Pediatric Attention-Deficit/Hyperactivity Disorder: Results from Two Randomized Placebo-Controlled Clinical Trials. Journal of the American Academy of Child & Adolescent Psychiatry. 50(1). 73–84.e1. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Axel Hinzpeter Breakdown of academic impact, for papers by N. Ueda Breakdown of academic impact, for papers by A. Penne Breakdown of academic impact, for papers by Luisa Sestito Breakdown of academic impact, for papers by Tatiana Vander Breakdown of academic impact, for papers by Kathy Chi‐Burris Breakdown of academic impact, for papers by Samantha Molsberry Breakdown of academic impact, for papers by Michael Peeters Breakdown of academic impact, for papers by Isabel Pastor
Rankless by CCL
2026